Lenzetto (Estradiol Hemihydrate)

Estradiol hemihydrate is an estrogen receptor agonist. After absorption through the skin, it binds to estrogen receptors in target tissues, triggering gene transcription that restores estrogenic activity. This action alleviates vasomotor symptoms, supports bone health, and normalizes hormonal balance in postmenopausal patients.

The specific dose of Lenzetto is determined by the prescribing clinician based on the patient’s clinical profile, severity of symptoms, and the strength of the selected patch. Dosage adjustments are made according to therapeutic response and safety monitoring.

Lenzetto is not recommended for use during pregnancy or while breastfeeding because systemic estrogen exposure may affect fetal development or milk production. Women of childbearing potential should use effective contraception and discuss any pregnancy plans with their healthcare provider.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenzetto delivers estradiol via a transdermal patch, providing more stable serum levels and bypassing first‑pass hepatic metabolism compared with oral estrogen tablets. This route can reduce gastrointestinal side effects and may have a lower impact on hepatic protein synthesis, making it a preferred option for many patients.

Lenzetto patches should be stored at room temperature, below 25 °C, in their original packaging. Keep them away from direct sunlight, moisture and excessive heat. Do not expose the patch to temperatures above the recommended range, as this may affect drug stability.

The patch is applied to clean, dry, hair‑free skin on the abdomen, buttock, or upper arm. Press firmly for several seconds to ensure adhesion, and rotate the application site with each new patch to minimize skin irritation. Follow the prescriber’s schedule for patch replacement.

Serious risks associated with Lenzetto include venous thromboembolism, stroke, myocardial infarction, endometrial hyperplasia or carcinoma, and severe allergic reactions. Patients should be educated to seek immediate medical attention for signs such as unexplained leg swelling, chest pain, sudden severe headache, or rash.

Lenzetto is contraindicated in women with known or suspected estrogen‑dependent malignancies, active or past thromboembolic disease, uncontrolled hypertension, severe liver disease, or known hypersensitivity to estradiol or any patch components. It should also be avoided in pregnant or breastfeeding women.